by Richard Daverman, PhD
September 3, 2013 -- Acebright Holdings of China announced new terms for its agreement with NasVax, an Israeli immunotherapy company. As before, Acebright will invest $1 million in NasVax. The company also signed a non-binding MOU that gives Acebright an exclusive right to develop NasVax’s oral Anti-CD3 technology for fatty liver disease in Asia Pacific countries including China, India and others, but excluding Japan. More details....
Stock Symbol: (TASE: NSVX)
Help employers find you! Check out all the jobs and post your resume.
